US3058979A - New perfluoroalkylphenothiazine derivatives - Google Patents

New perfluoroalkylphenothiazine derivatives Download PDF

Info

Publication number
US3058979A
US3058979A US658526A US65852657A US3058979A US 3058979 A US3058979 A US 3058979A US 658526 A US658526 A US 658526A US 65852657 A US65852657 A US 65852657A US 3058979 A US3058979 A US 3058979A
Authority
US
United States
Prior art keywords
carbon atoms
alkyl
trifluoromethylphenothiazine
solution
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US658526A
Inventor
Glenn E Ullyot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline and French Laboratories Ltd
Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline and French Laboratories Ltd filed Critical Smith Kline and French Laboratories Ltd
Priority to US658526A priority Critical patent/US3058979A/en
Priority to GB32856/57A priority patent/GB829246A/en
Priority to FR765378A priority patent/FR1293508A/en
Application granted granted Critical
Publication of US3058979A publication Critical patent/US3058979A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18[b, e]-condensed with two six-membered rings
    • C07D279/22[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C07D279/24[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
    • C07D279/28[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system

Definitions

  • the compounds of this invention have utility as antiemetics, tranquilizers, antihistaminics, spasmolytics, antishock agents and potentiators of various drugs such as analgetics and anesthetics.
  • tranquilizers When used as tranquilizers, these compounds have the ability to abate mental disturbances such as anxiety, confusion or excitation without physical incapacitation.
  • chemotherapeutic or anti-microbial activity such as antibacterial and fungicidal activity.
  • the novel compounds of this invention have a surprisingly low degree of toxicity.
  • the compounds of this invention are l0-(piperazinylalkyl) perfluoroalkylphenothiazine derivatives represented by the general formula:
  • Y represents perfiuoroalkyl of preferably -CF A represents a straight or branched alkylene chain of from 2 to 6 carbon atoms separating the nitrogen atoms linked thereto by at least two carbon atoms,
  • R is H or OH bonded to an internal methylene group in A, that is, not bonded to a carbon attached to a nitro- R R R and R each represent methyl, ethyl or hydrogen,
  • R represents the following:
  • Alkyl for example, methyl, ethyl, butyl hexyl, cyclopentyl and cyclohexyl,
  • Alicyclicalkyl of from 6 to 10 carbon atoms such as fl-cyclohexylethyl and [S-cyclopentylmethyl,
  • Alkenyl of from 2 to 6 carbon atoms such as allyl and isocrotonyl
  • Dialkylamino-lower-alkyl preferably dimethyl or diethylamino-lower-alkyl, for example, dimethylaminobutyl and diethylaminoethyl,
  • Hydroxy-lower-alkyl for example, hydroxyethyl and hydroxybutyl
  • Hydroxy-lower-alkyl-oxy-lower-alkyl for example, w-hY- droxyethoxyethyl and w-hYdIOXYPIOPOXYPIOPYl,
  • Monocyclic aralkyl for example, phenyl-lower-alkyl, such as benzyl, cinnamyl, phenethyl and w-phenylbutyl,
  • Acyl such as aliphatic acyl of from 1 to 6, preferably 1 to 4 carbon atoms, for example, formyl, acetyl, butyryl, propionyl, caproyl, isocaproyl, or crotonoyl or equivalently halogenated derivatives of said aliphatic acyls such as chloroacetyl, trifluoroacetyl, hepta- 3,583??? Patented Get. 16, 1962 are a. r
  • Acyloxy-lower-alkyl for example, aliphatic acyloxyloWer-alkyl having from 1 to 6, preferably from 2 to 4 carbon atoms in the acyloxy portion, such as, acetoxyethyl, crotonoyloxyethyl, butyryloxybutyl or isocaproyloxyethyl and monocyclic aroyloxy-loweralkyl such as benzoyloxy-lower-alkyl. Any of the acyl moieties defined above under acy can be used as substituents on the oxygen atom of the hydroxyloweralkyl moieties.
  • hydroxy-lower-allryl of from 2 to 4 carbon atoms or aliphatic acyloxy-lower-alkyl having 1 to 4 carbon atoms in the acyloxy portion and 2 to 4 carbon atoms in the alkyl portion.
  • alkyl where used herein, aliphatic groups having not more than 6 carbon atoms and, preferably not more than 4 carbon atoms, is intended except where otherwise specifically indicated.
  • lower alkyl is used in connection with alkylene residues and as thus used represents aliphatic groups of from 2 to 6 carbon atoms, preferably 2 to 4 carbon atoms except where otherwise specifically indicated.
  • This invention also includes salts of the above defined bases formed with non-toxic organic and inorganic acids.
  • Such salts are easily prepared by methods known to the art.
  • the base is reacted with either the calculated amount of organic or inorganic acid in aqueous miscible solvent, such as acetone or ethanol, with isolation of the salt by concentration and cooling, or an excess of the acid in aqueous immiscible solvent, such as ethyl ether or chloroform, with the desired salt separating directly.
  • aqueous miscible solvent such as acetone or ethanol
  • organic salts are those with maleic, fumaric, benzoic, ascorbic, pamoic, succinic, bismethylenesalicyclic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzene sulfonic and theophylline acetic acids as well as with the 8- halotheophyllines, for example, 8-chlorotheophylline and 8-bromotheophylline.
  • inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids.
  • these salts may also be prepared by the classical method of double decomposition of appropriate salts which is well-known to the art.
  • the compounds of this invention are prepared using Z-perfluoroalkylphenothiazine starting materials which are prepared by methods well-known to the art and most readily by classical methods of phenothiazine formation, such as thionation of properly substituted 2-perfluoroalkyldiphenyl amines, namely, Reference may be had to S. P. Massie, Chemical Reviews, 54; 797 (1954).
  • the 2-perfluoroalkylphenothiazine nucleus is condensed with a reactive piperazinylalkyl ester having the desired piperazinylalkyl group;
  • the condensation is carried out by refluxing the reactants in an inert aromatic solvent, such as benzene, xylene or toluene, in which at least one of the reactants must be soluble.
  • a suitable acid-binding agent may be included, such as an alkali metal amide, preferably sodium amide or potassium amide; an alkali metal hydroxide, preferably potassium hydroxide; an alkali metal hydride, preferably sodium hydride; or alkali metal aryl or alkyl compounds, preferably phenyl sodium.
  • the piperazinylalkyl ester is preferably used as the free base although the acid addition salts may be used with a corresponding increase in the amount of inorganic base as defined above.
  • Any reactive piperazinylalkyl ester containing the desired substituted piperazinylalkyl group may be used, such as the halides, preferably bromide or chloride, or the sulfonic or sulfuric ester, preferably the p-toluene sulfonate.
  • the 10- (piperazinylalkyl)-perfluoroalkylphenothiazines are alternatively prepared by methods which involve chemical modifications of an alkyl chain which has a reactive, terminal group such as a halogen, a carboxy, tosylate, aldehydo or cyano group and which is attached to the IO-position of the parent 2-perfluoroalkylphenothiazine.
  • the 2-perfluoroalkylphenothiazines substituted in the lO-position with an alkyl chain containing a terminal reactive ester group, such as tosylate are prepared as in the following procedure.
  • a Z-tetrahydropyranyl ether of a haloalkanol is condensed in an inert solvent, such as xylene, with a 2-perfluoroalkylphenothiazinc in the presence of an acid binder, such as sodamide, to give a 10-(w tetrahydropyranyloxyalkyl)-2-perfluoroalkylphenothiazine.
  • the protective pyranyl group is removed with acid, for example, hydrochloric acid.
  • the resulting 10-(w-hydroxyalkyl)-2-perfluoroalkylphenothiazine derivative is then esterified with an appropriate acyl halide, such as tosyl (p-toluene sulfonyl) chloride to give the desired reactive ester, in this case the tosylate.
  • an appropriate acyl halide such as tosyl (p-toluene sulfonyl) chloride
  • the resulting ester is reacted with a piperazine, preferably at reflux in alcohol with a mild alkali. This procedure is illustrated in the following scheme:
  • certain lO-(w-piperazinylalkyl)-2-perfiuoroalkylphenothiazine derivatives are prepared from the terminal primary amine derivatives by condensing a IO-(w-aminoalkyl)-2-perfluoroalkylphenothiazine (made readily by reduction of the w-cyanoalkyl'analogue) with a substituted bis-(fi-haloalkyD-amine, such as an alkylbis- (fl-haloalkyD- amine, to give a .10-[w (N-substitutedapiperazinyl)- alkyl]-perfluoroalkylphenothiazine such as a lO-[w-(N- alkylpiperazinyl) alkyl] perfluoroalkylphenothiazine as specifically illustrated in the following scheme showing the formation of the N-alkylpipe
  • N N-CHO The monosubstituted piperazine is heated at reflux with an excess of a formic acid ester, such as methyl or ethyl formate.
  • a formic acid ester such as methyl or ethyl formate.
  • the Volatiles are removed in vacuo and the desired N-formylpiperazinylalkyl ester isolated by distillation or fiactional crystallization.
  • the N- formylpiperazinylalkyl ester may be for-med by reversing the order of reaction, for instance by N-forrnylating w-hydroxy-lower-alkylpiperazine and then reacting with thionyl chloride to form N-(w-chloro lower-alkyl)-N- formylpiperazine.
  • This N-formyl ester is reacted with 2-perfluoroalkylphenothiazine to give l0-[e-(N-formylpiperazinyl) -alkyl] -2 perfluoroalkylphenothiazine.
  • the protective formyl group is removed by mild hydrolysis conditions, such as with dilute sodium hydroxide solution, to give the desired -(w-piperazinylalkyl)-2-perfluoroalkylphenothiazine.
  • a benzyl group it cannot be removed by hydrolysis but will be removed by catalytic hydrogenation.
  • This compound is further N-substituted by alkylation methods, such as with a reactive ester as discussed above in the presence of base, for instance with a substituted alkyl halide with sodium amide or potassium carbonate.
  • alkylation can be accomplished by reductive methods, for example, with formaldehyde-formic acid mixture, by reaction with an oxide such as ethylene oxide, or by N-acylation followed by reduction of the resulting amide, for instance N-acetylation followedby reduction with lithium aluminum hydride in tetrahydrofuran.
  • EXAMPLE I A mixture of 17.2 g. of 2-trifluoromethylphenothiazine, 3.1 g. of sodamide and 14 g. of 1-(3'-chloropropyl)-4- methylpiperazine in 200 ml. of xylene is heated at reflux with stirring for two hours. The salts are extracted into 150 ml. of water. The xylene layer is then extracted with several portions of dilute hydrochloric acid. The acid extracts are combined and neutralized with ammonium hydroxide solution.
  • 1-formyl-4-(3-chloropropyl)-piperazine [prepared by formylating 1-(3'-hydroxypropyl)- piperazine by refluxing in an excess of methyl formate, purifying the 1-formyl-4-(3-hydroxypropyl)-piperazine by vacuum distillation, reacting this compound with an excess of thionyl chloride at reflux and isolating the desired l-forrnyl-4(3'-chlor0propyl) -piperazine by neutralization with sodium carbonate solution followed by distillation] in 200 ml. of toluene is added. The reflux period is continued for four hours. The cooled reaction mixture is treated with 200 ml. of water.
  • the organic layer is extracted twice with dilute hydrochloric acid.
  • the acid extracts are made basic with ammonia and extracted with benzene.
  • the volatiles are taken ofl in vacuo at the steam bath to leave a dark brown oil which is 10-[3 (N formylpiperazinyl)-propyl] 2 trifluoromethylphenothiazine. It can be distilled at 260 C. at 10 microns, or used directly without distillation if desired.
  • EXAMPLE III A solution of 103.5 g. of 10-[3-(N-formylpiperazinyl)- propyl]-2-trifluoromethylphenothiazine (made as in Example II) in 400 ml. of ethanol and 218 ml. of water containing 26 ml. of 40% sodium hydroxide solution is heated at reflux for two hours. The alcohol is taken oif in vacuo on the steam bath. The residue is swirled with benzene and water. The dried benzene layer is evaporated in vacuo.
  • This material 3.9 g., is dissolved in ethyl acetate and reacted with 2.4 g. of maleic acid. Concentration and cooling gives the crystalline dimaleate which, after drying at C. in an Abderhalden pistol, melts at 142 C. as the hemihydrate salt.
  • EXAMPLE IV A suspension of 14.0 g. of 10-(3'-piperazinylpropyl)- Z-trifluoromethylphenothiazine (made as in Example III), 6.4 g. of ,B-bromoethyl acetate and 2.6 g. of potassium carbonate in 100 ml. of toluene is stirred at reflux for 16 hours. Water (50 ml.) is added to the cooled mixture. The organic layer is extracted into dilute hydrochloric acid. After neutralizing the extracts and taking the separated base up in benzene, a viscous, yellow residue is obtained by evaporating the organic solvent in vacuo. This oil is chromatographed on alumina.
  • the acid ctumarate salt of this base is prepared by combining 4.2 g. of the base with 2.6 g. of fumaric acid in ethanol'an'd adding ether to cloudiness. The mixture is then cooled in a Dry Ice/isopropanol bath to separate the desired difumarate salt.
  • EXAMPLE VI A mixture of 10 g. of l0-(2'-piperazinylethyl)-2-trifluoromethylphenothiazine (prepared as in Example V) in 50 ml. of 85% formic acid solution is warmed to 50 C. and ml. of 37% formalin solution is added over a 15 minute period. The reaction mixture is held at 50 to 60 C. until the evolution of carbon monoxide ceases. The mixture is neutralized with dilute sodium hydroxide solution to give an insoluble oil.
  • EXAMPLE VIII Sixteen grams of 10-(2-cyanoethyl) -2-tri fluoromethylphenothiazine (prepared by reacting Z-tn'fluoromethylphenothiazine with. acrylonitrile under alkaline conditions) is suspended in 500 m1. of dry ethyl ether. A solution of 8 g. of lithium aluminum hydride in250 ml. of
  • the basic residue is fractionally distilled to give an oily base, l0-[3-(4"-'butyl 1" piperazinylJ-propyl]-2-trifluoromethylphenothiazine, B.P. 202 to 207 C. at 0.05 mm.
  • EXAMPLE IX 7 EXAMPLE x A suspension of 3.9 g. of 10-(3'-piperazinylpropyl)-2 trifluoromethylphenothiazine (made as in Example III), 2.0 g. of 2-bromo-l-diethylaminoethane and 0.5 g. of sodium amide in 50 ml. of benzene is heated at reflux with stirring for six hours.”
  • the water-washed aminobenzoic acid (225 g.) is decarboxylated by heating at 200 C. until the evolution of carbon dioxide ceases.
  • a mixture of 33.5 g. of the resulting crude solid, 3-heptafluoropropyldiphenylamine, and 17.4 g. of sulfur and 0.3 g. of iodine is heated at 160180 C. until the evolution of hydrogen sulfide ceases.
  • the reaction mass is then extracted with hot benzene. Concentration and cooling separates greenish yellow platelets of 2-l1eptafluoropropylphenothiazine.
  • EXAMPLE XV A suspension of 3.9 g. of 10-(3-piperazinylpropyl) -2- trifluoromethylphenothiazine (made as in Example III), 2.3 g. of n-hexyl iodide and 4.0 g. of potassium carbonate in 75 ml. of xylene is heated at reflux with stirring for eight hours. The reaction mixture is filtered. The filtrate is Washed with water, dried and concentrated.
  • EXAMPLE XVIII A solution of 3.8 g. of 10-(2'-piperazinylethyl)-2-trifluoromethylphenothiazine (made as in Example V) in 150 g. of benzene with 4 ml. of pyridine is swirled while 3 ml. of acetic anhydride are added. The reaction mixture is allowed to stand overnight and evaporated to dryness. The residue after the usual acid extraction and neutralization is taken up in ethyl acetate and reacted with one equivalent of maleic acid to give 10-[2- (N acetylpiperazinyl) ethyl] 2 trifluoromethylphenothiazine maleate.
  • EXAMPE XXV A suspension of 36.7 g. of 2hepta-fluoropropylpheno thiazine (made as in Example XIV), 4.0 g. of sodium amide and 27.5 g. of N-diethylcarbamyl-N-('y-chloropropyl)-piperazine (prepared by reacting N-diethylcarbamylpiperazine with -chloropropyl bromide in xylene with sodium amide in 300 ml. of toluene is heated at reflux for six hours.
  • the reaction mixture containing 10 [3' (N-carbobenzoxy 2",5 diethylpiperazinyD- propyl]-2-trifluoromethylphenothiazine is 'Washed With Water and treated with dilute hydrochloric acid. The acid extracts are warmed briefly, cooled and treated With sodium hydroxide solution. The separated base is taken up in ethyl acetate, dried and micromolecularly distilled to give the thick base 10-[3'-(27,5":diethylpiperazinyl)- propyl]-2-trifluoromethylphenothiazine.
  • V A solution of 3.2 g. of the base in 75 ml. of benzene is heated at reflux with 1.2 g.
  • EXAMPLE XXXH A solution of 31.1 g. of 10-[3-(N-hydroxyethylpiperazinyl)propyl]-2atrifluoromethylphenothiazine in 500 ml. of benzene is prepared as in Example VII. From the stock solution, an aliquot solution containing 3.2 g. of the hydroxyethyl compound is heated briefly at reflux with 1.0 g. of propionyl chloride. A small excess of ethanolic hydrogen chloride is added. The precipitated product is 10-[3'-(N-propionyloxyethylpiperazinyl)-propyl] 2 trifluoromethylphenothiazine dihydrochloride, M.P. 2l2-214 C.
  • a second aliquot solution containing 3.2 g. of the hydroxyethyl base is reacted with 1.5 g. of dichloroacetyl chloride as above.
  • the product is 10-[3-(N-dichloroacetoxyethylpip er azinyl) -propy-l] -2-trifluoromethylphenothiazine dihydrochloride.
  • Crotonic chloride 1.0 g., is reacted with an aliquot of the hydroxyethyl base as above.
  • the separated monohydrochloride of [3'-(N-crotonyloxyethylpiperazinyl)- propyl]-2 trifluoromethylphenothiazine is separated by filtration and washed with ether.
  • the base (5.4 g.) is alkylated with 2.6 g. of thenyl chloride as above.
  • the dim-aleate salt of 10-[3'-(N- thenyl-piperazinyl)-propyl] 2 trifluoromethylphenothiazine is obtained by reacting the crude base with an excess of maleic acid in ethyl acetate solution.
  • Y is perfluoroalkyl of 1 to 3 carbon atoms
  • A is an alkylene chain of from 2 to 6 carbon atoms separating the nitrogen atoms linked thereto by at least two carbon atoms
  • R is a member selected from the group consisting of cycloalkyl-lower-alkyl, the cycloalkyl portion having 5 to 6 carbon atoms and the lower-alkyl portion having 1 to 4 carbon atoms, lower alkenyl having 3 to 6 carbon atoms, hydroxy-lower-allcyl having 2 to 6 carbon atoms in the alkyl portion, hydroxy-lower-alkyloxy-lower-alkyl, the lower alkyl portions having 2 to 6 carbon atoms, phenyl, phenyl-lower-alkyl having 1 to 6 carbon atoms in the alkyl portion, lower-alkanoyl having 1 to 6 carbon atoms, cycloalkyl-lower-alkanoyl, the cyclo
  • LJ v FOREIGN PATENTS 7 A chemical compound of the formula: 293/55 South Africa Au0 22 1955 v V V a- I /S CF11 i N j p I

Description

3,058,979 NEW PERFLUGROALKYLPHENUTZWE DERIVATIVES Glenn E. Ullyot, Philadelphia, Pa, assignor to Smith Kline & French Laboratories, Philadelphia, Pa, a corporation i Pennsylvania No Drawing. Filed May 13, 1957, Ser. No. 658,526 12 Claims. (Cl. 260-243) This invention relates to new lO-(piperazinylalkyl) -perfluoroalkylphenothiazine derivatives. The novel com pounds of this invention are of value as therapeutic agents.
More specifically, the compounds of this invention have utility as antiemetics, tranquilizers, antihistaminics, spasmolytics, antishock agents and potentiators of various drugs such as analgetics and anesthetics. When used as tranquilizers, these compounds have the ability to abate mental disturbances such as anxiety, confusion or excitation without physical incapacitation. In addition, these compounds have chemotherapeutic or anti-microbial activity, such as antibacterial and fungicidal activity. Further, the novel compounds of this invention have a surprisingly low degree of toxicity.
The compounds of this invention are l0-(piperazinylalkyl) perfluoroalkylphenothiazine derivatives represented by the general formula:
when:
Y represents perfiuoroalkyl of preferably -CF A represents a straight or branched alkylene chain of from 2 to 6 carbon atoms separating the nitrogen atoms linked thereto by at least two carbon atoms,
R is H or OH bonded to an internal methylene group in A, that is, not bonded to a carbon attached to a nitro- R R R and R each represent methyl, ethyl or hydrogen,
R represents the following:
1 to 3 carbon atoms,
Hydrogen,
Alkyl, for example, methyl, ethyl, butyl hexyl, cyclopentyl and cyclohexyl,
Alicyclicalkyl of from 6 to 10 carbon atoms, such as fl-cyclohexylethyl and [S-cyclopentylmethyl,
Alkenyl of from 2 to 6 carbon atoms such as allyl and isocrotonyl,
Dialkylamino-lower-alkyl preferably dimethyl or diethylamino-lower-alkyl, for example, dimethylaminobutyl and diethylaminoethyl,
Hydroxy-lower-alkyl, for example, hydroxyethyl and hydroxybutyl,
Hydroxy-lower-alkyl-oxy-lower-alkyl, for example, w-hY- droxyethoxyethyl and w-hYdIOXYPIOPOXYPIOPYl,
Monocyclic aralkyl, for example, phenyl-lower-alkyl, such as benzyl, cinnamyl, phenethyl and w-phenylbutyl,
Acyl such as aliphatic acyl of from 1 to 6, preferably 1 to 4 carbon atoms, for example, formyl, acetyl, butyryl, propionyl, caproyl, isocaproyl, or crotonoyl or equivalently halogenated derivatives of said aliphatic acyls such as chloroacetyl, trifluoroacetyl, hepta- 3,583??? Patented Get. 16, 1962 are a. r
fluorobutyryl and dichloroacetyl; 'alicyclic aliphatic acyl of from 7 to 10 carbon atoms, such as cyclopentylpropionyl, hexahydrobenzoyl and cyclohexylbutyryl; monocyclic aryl-aliphatic acyl of from 6 to 10 carbons, such as cinnamoyl, phenylacetyl, phenylpropionyl or Z-furaneacrylyl; monocyclic aroyl such as furoyl or benzoyl; lower carbalkoxy, such as carbomethoxy or carbethoxy; carbobenzoxy; carbarnyl and N-substituted carbamyl, for example, dialkyl carbamyl such as diethylcarbamyl or dimethylcarbamyl and N- phenyl carbamyl,
Acyloxy-lower-alkyl, for example, aliphatic acyloxyloWer-alkyl having from 1 to 6, preferably from 2 to 4 carbon atoms in the acyloxy portion, such as, acetoxyethyl, crotonoyloxyethyl, butyryloxybutyl or isocaproyloxyethyl and monocyclic aroyloxy-loweralkyl such as benzoyloxy-lower-alkyl. Any of the acyl moieties defined above under acy can be used as substituents on the oxygen atom of the hydroxyloweralkyl moieties.
Advantageous compounds of this invention are rep resented by the above structural formula when:
hydroxy-lower-allryl of from 2 to 4 carbon atoms or aliphatic acyloxy-lower-alkyl having 1 to 4 carbon atoms in the acyloxy portion and 2 to 4 carbon atoms in the alkyl portion.
By the term alkyl where used herein, aliphatic groups having not more than 6 carbon atoms and, preferably not more than 4 carbon atoms, is intended except where otherwise specifically indicated.
The term lower alkyl is used in connection with alkylene residues and as thus used represents aliphatic groups of from 2 to 6 carbon atoms, preferably 2 to 4 carbon atoms except where otherwise specifically indicated.
It is also implied, as one skilled in the art will recognize, that when R is hydroxy, it is not attached to the end members of the alkylene chain.
This invention also includes salts of the above defined bases formed with non-toxic organic and inorganic acids. Such salts are easily prepared by methods known to the art. The base is reacted with either the calculated amount of organic or inorganic acid in aqueous miscible solvent, such as acetone or ethanol, with isolation of the salt by concentration and cooling, or an excess of the acid in aqueous immiscible solvent, such as ethyl ether or chloroform, with the desired salt separating directly. Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, pamoic, succinic, bismethylenesalicyclic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzene sulfonic and theophylline acetic acids as well as with the 8- halotheophyllines, for example, 8-chlorotheophylline and 8-bromotheophylline. Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids. Of course, these salts may also be prepared by the classical method of double decomposition of appropriate salts which is well-known to the art.
The compounds of this invention are prepared using Z-perfluoroalkylphenothiazine starting materials which are prepared by methods well-known to the art and most readily by classical methods of phenothiazine formation, such as thionation of properly substituted 2-perfluoroalkyldiphenyl amines, namely, Reference may be had to S. P. Massie, Chemical Reviews, 54; 797 (1954).
The 2-perfluoroalkylphenothiazine nucleus is condensed with a reactive piperazinylalkyl ester having the desired piperazinylalkyl group; The condensation is carried out by refluxing the reactants in an inert aromatic solvent, such as benzene, xylene or toluene, in which at least one of the reactants must be soluble. A suitable acid-binding agent may be included, such as an alkali metal amide, preferably sodium amide or potassium amide; an alkali metal hydroxide, preferably potassium hydroxide; an alkali metal hydride, preferably sodium hydride; or alkali metal aryl or alkyl compounds, preferably phenyl sodium.
The piperazinylalkyl ester is preferably used as the free base although the acid addition salts may be used with a corresponding increase in the amount of inorganic base as defined above. Any reactive piperazinylalkyl ester containing the desired substituted piperazinylalkyl group may be used, such as the halides, preferably bromide or chloride, or the sulfonic or sulfuric ester, preferably the p-toluene sulfonate.
The 10- (piperazinylalkyl)-perfluoroalkylphenothiazines are alternatively prepared by methods which involve chemical modifications of an alkyl chain which has a reactive, terminal group such as a halogen, a carboxy, tosylate, aldehydo or cyano group and which is attached to the IO-position of the parent 2-perfluoroalkylphenothiazine. While such methods are conveniently used to prepare 10-(N-substituted-piperazinylalkyl)-2 perfluoroalkylphenothiazine, they are particularly valuable for the preparation of the piperazines unsubstituted at the terminal N position, such as IO-(w-piperazinylalkyl)-2-perfluoroalkylphenothiaziue or l-[w-(2',5-diethylpipera2inyl) alkyl]-2-perfluoroalkylphenothiazine. These synthetic procedures will be more evident from the following description.
For example, the 2-perfluoroalkylphenothiazines substituted in the lO-position with an alkyl chain containing a terminal reactive ester group, such as tosylate, are prepared as in the following procedure. A Z-tetrahydropyranyl ether of a haloalkanol is condensed in an inert solvent, such as xylene, with a 2-perfluoroalkylphenothiazinc in the presence of an acid binder, such as sodamide, to give a 10-(w tetrahydropyranyloxyalkyl)-2-perfluoroalkylphenothiazine. The protective pyranyl group is removed with acid, for example, hydrochloric acid. The resulting 10-(w-hydroxyalkyl)-2-perfluoroalkylphenothiazine derivative is then esterified with an appropriate acyl halide, such as tosyl (p-toluene sulfonyl) chloride to give the desired reactive ester, in this case the tosylate. The resulting ester is reacted with a piperazine, preferably at reflux in alcohol with a mild alkali. This procedure is illustrated in the following scheme:
/ V ClSOz-CHa E N Y s i n: Ra
H-N N-Ra Y N/ I R4 s A-O-SOz-Q-QH;
N Y l R: R3
-N V N-Ra the Bernthsen reaction.
It is, at times, convenient to react the l0-(w-hydroxyalkyl)-perfluoroalkylphenothiazine derivative obtained as hereabove described with a reactive inorganic halide, such as thionyl chloride, thionyl bromide or phosphorous pentachloride, in a non-ionic solvent, such as benzene or xylene, to give a 10-(w-haloalkyl) -perfluoroalkylphenothiazine which is then reacted with a piperazine preferably in excess or in the presence of an acid binder, such as sodium carbonate in an aqueous alcohol medium.
As a further example of the preparation of these compounds, certain lO-(w-piperazinylalkyl)-2-perfiuoroalkylphenothiazine derivatives are prepared from the terminal primary amine derivatives by condensing a IO-(w-aminoalkyl)-2-perfluoroalkylphenothiazine (made readily by reduction of the w-cyanoalkyl'analogue) with a substituted bis-(fi-haloalkyD-amine, such as an alkylbis- (fl-haloalkyD- amine, to give a .10-[w (N-substitutedapiperazinyl)- alkyl]-perfluoroalkylphenothiazine such as a lO-[w-(N- alkylpiperazinyl) alkyl] perfluoroalkylphenothiazine as specifically illustrated in the following scheme showing the formation of the N-alkylpiperazinyl derivatives:
X as used in the above and following scheme equals halogen.
Easily removed groups may be substituted for the -alkyl radical, such as where R is acyl, in order to obtain the compounds of this invention in which R is H by this method. This is the best synthetic route for the preparation of the compounds where R is H which compounds are particularly important as intermediates to prepare analogues with other R substituents by reaction with reactive esters such as bromides, iodides or chlorides or with ethylene oxide. This route of synthesis conveniently gives compounds of this invention in good yield and purity which would be obtained otherwise with more difiiculty. For example, the production of 10-(w piperazinylalkyl) 2 perfluoroalkylphenothiazines may be accomplished by protecting the nitrogen of the piperazinylalkyl ester with a formyl group by the following procedure:
N N-CHO The monosubstituted piperazine is heated at reflux with an excess of a formic acid ester, such as methyl or ethyl formate. The Volatiles are removed in vacuo and the desired N-formylpiperazinylalkyl ester isolated by distillation or fiactional crystallization. Optionally, the N- formylpiperazinylalkyl ester may be for-med by reversing the order of reaction, for instance by N-forrnylating w-hydroxy-lower-alkylpiperazine and then reacting with thionyl chloride to form N-(w-chloro lower-alkyl)-N- formylpiperazine. This N-formyl ester is reacted with 2-perfluoroalkylphenothiazine to give l0-[e-(N-formylpiperazinyl) -alkyl] -2 perfluoroalkylphenothiazine. The protective formyl group is removed by mild hydrolysis conditions, such as with dilute sodium hydroxide solution, to give the desired -(w-piperazinylalkyl)-2-perfluoroalkylphenothiazine. However, when a benzyl group is used, it cannot be removed by hydrolysis but will be removed by catalytic hydrogenation.
This compound is further N-substituted by alkylation methods, such as with a reactive ester as discussed above in the presence of base, for instance with a substituted alkyl halide with sodium amide or potassium carbonate. Alternatively, the alkylation can be accomplished by reductive methods, for example, with formaldehyde-formic acid mixture, by reaction with an oxide such as ethylene oxide, or by N-acylation followed by reduction of the resulting amide, for instance N-acetylation followedby reduction with lithium aluminum hydride in tetrahydrofuran.
The foregoing is a general description of the main synthetic routes in the preparation of l0-(wpiperazinylalkyl)-2-perfluoroalkylphenothiazine derivatives. It will be readily apparent to one skilled in the art that variations of these procedures are possible. Of particular advantage as preparative procedures are the first two methods discussed, namely, alkylation of 2-perfluoroalkylphenothiazine in the l0-position of the nucleus by a reactive dialkylaminoalkyl ester and utilization of 2-perfluoroalkylphenothiazine derivatives substituted in the 10'- position with aliphatic chains containing a reactive terminal group.
It will be readily apparent to one skilled in the art that certain of the compounds of this invention, notably those in which A is represented by an aliphatic carbon chain branched so that an asymmetric carbon atom is formed or where the w-piperazinyl moiety is C-substituted, may be present as optical or cis-trans isomers. The connotation of the general formulae presented herein is to include the separated d. or 1. optical isomers as well as the d1. mixture of these isomers. If desired, the isomers may be separated for individual use by separation methods known to the art, such as fractional crystallization of the d-tartrate salts of the perfluoroalkylphenothiazine derivatives. Alternatively, a synthesis starting with an optically active side chain may yield the desired optical isomer.
The following examples will be illustrative of compounds of this invention and the procedures for their preparation and will serve to make fully apparent all of the compounds embraced by the general formula given above and the preparation thereof respectively.
EXAMPLE I A mixture of 17.2 g. of 2-trifluoromethylphenothiazine, 3.1 g. of sodamide and 14 g. of 1-(3'-chloropropyl)-4- methylpiperazine in 200 ml. of xylene is heated at reflux with stirring for two hours. The salts are extracted into 150 ml. of water. The xylene layer is then extracted with several portions of dilute hydrochloric acid. The acid extracts are combined and neutralized with ammonium hydroxide solution. The products, 10-[3-(4- methyl-1"-piperazinyl)-propyl] -2 trifluoromethylphenothiazine, is taken into benzene and purified by vacuumdistillation, B.P. 202 to 210 C. at 0.6 mm.
Four grams of the basic oil are treated with 2.2 g. of
maleic acid in ethyl acetate. Cooling the concentrated solution caused the separation of crystals of 10-[3-(4"- methyl-l"-piperazinyl) -propyl] -2 trifluoromethylphenothiazine dimaleate; M.P. 185 C. (dec.).
EXAMPLE II A suspension of 69.0 g. of 2-trifluoromethylphenothiazinc in l l. of toluene with 10.9 g. of sodium amide is heated at reflux with high speed stirring for 15 minutes. A solution of 54.1 g. of 1-formyl-4-(3-chloropropyl)-piperazine, [prepared by formylating 1-(3'-hydroxypropyl)- piperazine by refluxing in an excess of methyl formate, purifying the 1-formyl-4-(3-hydroxypropyl)-piperazine by vacuum distillation, reacting this compound with an excess of thionyl chloride at reflux and isolating the desired l-forrnyl-4(3'-chlor0propyl) -piperazine by neutralization with sodium carbonate solution followed by distillation] in 200 ml. of toluene is added. The reflux period is continued for four hours. The cooled reaction mixture is treated with 200 ml. of water. The organic layer is extracted twice with dilute hydrochloric acid. The acid extracts are made basic with ammonia and extracted with benzene. The volatiles are taken ofl in vacuo at the steam bath to leave a dark brown oil which is 10-[3 (N formylpiperazinyl)-propyl] 2 trifluoromethylphenothiazine. It can be distilled at 260 C. at 10 microns, or used directly without distillation if desired.
EXAMPLE III A solution of 103.5 g. of 10-[3-(N-formylpiperazinyl)- propyl]-2-trifluoromethylphenothiazine (made as in Example II) in 400 ml. of ethanol and 218 ml. of water containing 26 ml. of 40% sodium hydroxide solution is heated at reflux for two hours. The alcohol is taken oif in vacuo on the steam bath. The residue is swirled with benzene and water. The dried benzene layer is evaporated in vacuo. The residue is vacuum distilled to give a viscous, yellow oil, 10-(3'-piperazinylpropyl)-2-triflu0- romethyl-phenothiazine, distilling at 210-235 C. at 0.5 to 0.6 mm.
' This material, 3.9 g., is dissolved in ethyl acetate and reacted with 2.4 g. of maleic acid. Concentration and cooling gives the crystalline dimaleate which, after drying at C. in an Abderhalden pistol, melts at 142 C. as the hemihydrate salt.
EXAMPLE IV A suspension of 14.0 g. of 10-(3'-piperazinylpropyl)- Z-trifluoromethylphenothiazine (made as in Example III), 6.4 g. of ,B-bromoethyl acetate and 2.6 g. of potassium carbonate in 100 ml. of toluene is stirred at reflux for 16 hours. Water (50 ml.) is added to the cooled mixture. The organic layer is extracted into dilute hydrochloric acid. After neutralizing the extracts and taking the separated base up in benzene, a viscous, yellow residue is obtained by evaporating the organic solvent in vacuo. This oil is chromatographed on alumina. The purified fraction of 7.7 g. of l0-[3-(N-acetoxyethylpiperazinyl)-propyl]-2-trifluoromethylphenothiazine is taken up in ethyl acetate and mixed with 25 ml. of alcoholic hydrogen chloride. Concentration in vacuo separates white crystals of the dihydrochloride salt, M.P. 225-227 C.
EXAMPLE V A solution of 33 g. of 10-(2 chloroethyl)-2-trifluoromethylphenothiazine (prepared by the reaction of ethylene oxide with Z-trifluoromethylphenothiazine followed by subsequent treatment of the li-hydroxyethyl compound with thionyl chloride) and 25 g. of anhydrous piperazine in 200 ml. of isoarnyl alcohol is heated at reflux for twelve hours. The reaction mixture is then washed well with water. The organic layer is extracted with dilute hydrochloric acid. After neutralizing with ammonia and extracting with ethyl acetate, drying and evaporating the acetate extracts gives 5 g. of the crude base, 10-(2'-piperazinylethyl) -Ltrifluoromerhylphenothiazine. After molecnlardistillation of the residue, the dirnaleate is prepared in ethyl acetate solution following the procedure of ExampleI. V M 7 Three grams of the base is heated at reflux in aqueous methanol with one equivalent of ethyl p-toluenesulphonate with sodium carbonate for ten hours. The strongly basic residue after evaporation is extracted with ether. The dried ether extracts are combined and treated with gaseous hydrogen chloride to give crude [2'-( -ethyl- 1"-piperazinyl) -ethyl] -2-trifluorornethylphenothiazine dihydrochloride, M.P. 2l0215 C. (dec.).
The acid ctumarate salt of this base is prepared by combining 4.2 g. of the base with 2.6 g. of fumaric acid in ethanol'an'd adding ether to cloudiness. The mixture is then cooled in a Dry Ice/isopropanol bath to separate the desired difumarate salt.
EXAMPLE VI A mixture of 10 g. of l0-(2'-piperazinylethyl)-2-trifluoromethylphenothiazine (prepared as in Example V) in 50 ml. of 85% formic acid solution is warmed to 50 C. and ml. of 37% formalin solution is added over a 15 minute period. The reaction mixture is held at 50 to 60 C. until the evolution of carbon monoxide ceases. The mixture is neutralized with dilute sodium hydroxide solution to give an insoluble oil. This base is extracted into benzene and vacuum distilled to give 10-[2'.-(4"- methyl 1" piperazinyl)-ethyl]-2-trifluoromethylphenothiazine as-a clear-oil, B.P. 205 to 210 C. at 0.5 mm.
A solution of 500 mg. of the base in ethyl acetate is saturated with dry hydrogen chloride gas. 'Irituration with ether separates crystals of the dihydrochloride salt, M.P. 253 C.
' EXAMPLE VII A solution of 1.0 g. of 10-[3'-(N-acetoxyethylpiperazinyl)-propyl]-2-trifluoromethylphenothiazine (made as in Example IV) in 25 ml. of 1 N hydrochloric acid is heated at reflux briefly. Neutralization with dilute so- .dium carbonate solution and extraction with benzene gives the oily base, 10-[3'-(N-[i-hydroxyethylpiperazinyl)-propyl]-2-trifluoromethylphenothiazine. The base is reacted with an excess of an alcoholic hydrogen chloride solution. Trituration with ether separates crystals of the dihydrochloride salt, M.P. 224-226 C.
EXAMPLE VIII Sixteen grams of 10-(2-cyanoethyl) -2-tri fluoromethylphenothiazine (prepared by reacting Z-tn'fluoromethylphenothiazine with. acrylonitrile under alkaline conditions) is suspended in 500 m1. of dry ethyl ether. A solution of 8 g. of lithium aluminum hydride in250 ml. of
[ether is slowly added. The reaction mixture is then heated at reflux with stirring for 24 hours. The complex is carefully destroyed by the addition of methanol. After filtration, the filtrate is evaporated in vacuo. The residue is extracted with, several 50 ml, portions of 10% hydrochloric acid. The combined acid extracts are neutralized with concentrated ammonium hydroxide solution. The separatedsbase is taken into dry ether and treated with gaseous hydrogen chloride to give 10-(3'-aminopropy1)- 2-trifluoromethylphenothiazine hydrochloride.
A solution of 32.5 g. of l0-'(3'-aminopropyl)-2-tri fluoromethylphenothiazine, 21 g. of butyl bis-(fl-chloroeth D-amine in 300 ml. of butanol is heated at reflux for eight hours. Tributylamine (40 ml.) is added to the mixture and the reflux period is extended for eight hours. The volume of the reaction mixture is reduced on-the steam bath at the water pump. After dilution of the residue with water, the base is extracted into chloroform. The dried chloroform extracts are concentrated. The basic residue is fractionally distilled to give an oily base, l0-[3-(4"-'butyl 1" piperazinylJ-propyl]-2-trifluoromethylphenothiazine, B.P. 202 to 207 C. at 0.05 mm.
. phenothiazine.
i recrystallizing the resulting salt a?! e "A solution of 800 mg. of the base in 25 ml. of ethyl acetate-ethanol is treated with 500 mg. of citric acid in ethanol. Concentration and cooling separates the dicitrate salt.
" EXAMPLE IX 7 EXAMPLE x A suspension of 3.9 g. of 10-(3'-piperazinylpropyl)-2 trifluoromethylphenothiazine (made as in Example III), 2.0 g. of 2-bromo-l-diethylaminoethane and 0.5 g. of sodium amide in 50 ml. of benzene is heated at reflux with stirring for six hours."
distillation, at 195 .C. at 1 micron.
EXAMPLE XI A mixture of 18 g. of the 10-(3'-chloro-2'methylpropyl)-2-trifluoron1ethylphenothiazine (prepared by the condensation of 1-brorno-3-chloro-2-methylpropane with 2-trifluoromcthylphenothiazine) and 25 g. of N-methylpiperazine in ml. of methanol is three days. The volatiles are removed in vacuo on the steam bath. The residue is shaken with sodium hydroxide pellets and washed with 100 ml. portions of water, then extracted with benzene. The dried and washed organic extracts are evaporated at the water pump to give crude 1O [2-methyl-3'-(4"-methyl-l"-piperazinyD-propyl]-2-trifluoromethylphenothiazine'which is purified by forming the dihydrochloride salt by reacting the base with ethereal hydrogen chloride in ethyl acetate and then from' ethanol/ether. The dihydrochloride salt melts at either 167-l68 C., or -186" C., depending on which polymorphic form is prepared.
' 'EXAMPLE'XII A solution of 24.0 g. of l0-(3'-hydroxypropyl)-2-trifiuoromethylphenothiazine p toluene sulfonate (prepared by reacting Z-trifluoromethylphenothiazine with 'ybromopropyltetrahydropyranyl ether, removing the protective group with mineral acidand acylating with tosyl chloride in pyridine), 20.0 g. of N-hydroxyethoxyethylpiperazine in 300 ml. of ethanol with 10.0 g. of potassium carbonate is heated for six hours with stirring. The solution is diluted with water, evaporated in vacuo and extracted with ethyl acetate. The dried organic extract is evaporated to leave a crude syrup of 10- [3-(N-hydroxyethoxyethylpiperazinyl) propyl] 2 trifluoromethyl- EXAMPLE XIII A solution of 13.4 g. of 2-trifluoromethylphenothiazine, 12.0 g. of N-w-chlorohexyl-Nqnethylpiperazine and 2.0 g. of sodamide in ZSO. of xylene is heated at reflux for 40 hours- Afterworking up the; reaction mixture by the procedureof Example I, a crude syrup, 10-[6'-(N- methylpiperazinyl) hexyl] 2 trifluoromethylphenothiaz ine, is isolated. 0 a a A solution of 2.0 g. ofthisbase dissolved in ether is saturated with dry hydrogen bromide gas to separate crystals of the dihydrobromide salt, I
Thereaction mixture is isolated. by the procedure of .Example I. The crude syrup, l0-- [3 (,8 --N diethylaminoethylpiperazinyl) propyl] 2-trifluoromethylphenothiazine, is purified by molecular 1 heated at reflux for 9 EXAMPLE xrv Heptafluoropropylbenzene (180 g.) is slowly added to a mixture of nitric acid (d. 1.5) and concentrated sulfuric acid while maintaining the temperature at 2030 .C. The reaction mixture is quenched in an ice slurry, taken up in benzene and dried. Distillation at 100 C. at mm. gives l-heptafluoropropyl-3-nitrobenzene. A mixture of 125 g. of this compound in 300 ml. of purified dioxane is reduced at 2,000 p.s.i. with g. of Raney nickel catalyst. Dilution with benzene, filtering the catalyst and evaporation gives a residue, 3-heptafluoropropylaniline, B.P. 95 to 96 C. at 12 mm.
Equivalent amounts of potassium carbonate, 2-chlorobenzoic acid and the aniline with 5.0 g. of copper powder in 500 ml. of amyl alcohol are heated at reflux with stirring for 24 hours. The basic reaction mixture is subjected to steam distillation. The residue is an aqueous slurry of the desired product as the sodium salt, 2-(3'- heptailuoropropylphenylamino)-benzoic acid. The free acid is obtained by trituration with excess dilute hydrochloric acid.
The water-washed aminobenzoic acid (225 g.) is decarboxylated by heating at 200 C. until the evolution of carbon dioxide ceases. A mixture of 33.5 g. of the resulting crude solid, 3-heptafluoropropyldiphenylamine, and 17.4 g. of sulfur and 0.3 g. of iodine is heated at 160180 C. until the evolution of hydrogen sulfide ceases. The reaction mass is then extracted with hot benzene. Concentration and cooling separates greenish yellow platelets of 2-l1eptafluoropropylphenothiazine.
A suspension of 20.0 g. of Z-heptafluoropropylphenothiazine, 10.0 g. of 3-chloro-1-(N-methylpiperazinyl)- propane and 1.5 g. of lithium amide in 300 ml. of toluene is heated at reflux for four hours. After working up the mixture as in Example I, a viscous syrup, 2-heptafluoropropyl 10 [3 (N methylpiperazinyl) propyl]-phenothiazine, is obtained by molecular distillation at 205 C. and 15 microns.
A solution of 2.0 g. of this base in ml. of ethyl acetate is reacted with a slight excess of maleic acid in ethyl acetate. Concentration and cooling gives the dimaleate salt.
EXAMPLE XV A suspension of 3.9 g. of 10-(3-piperazinylpropyl) -2- trifluoromethylphenothiazine (made as in Example III), 2.3 g. of n-hexyl iodide and 4.0 g. of potassium carbonate in 75 ml. of xylene is heated at reflux with stirring for eight hours. The reaction mixture is filtered. The filtrate is Washed with water, dried and concentrated. The residue is weighed, taken up in ethyl acetate and treated with two equivalents of maleic acid to give crude 10 [3 (N hexylpiperazinyl) propyl] 3 trifluoromethylphenothiazine dimaleate, which is recrystallized from ethanol.
EXAMPLE XVI A suspension of 7.8 g. of 10-(3'-piperazinylpropyl)-2 trifluoromethylphenothiazine (made as in Example III), 3.4 g. of w-bromobutanol and 8.0 g. of potassium carbonate in 150 ml. of xylene is heated at reflux with stirring for five hours. After working up the reaction mixture as in Example XV, and distilling the crude basic residue, a viscous syrup is obtained, 10-[3-(N-w-hydroxybutylpiperazinyl) propyl] 2 trifluoromethylphenothiazine.
A solution of 1.1 g. of the base is dissolved in 25 ml. of pyridine and 0.5 ml. of butyryl chloride is added. After standing at room temperature for 12 hours, the reaction mixture is quenched. The separated product is washed well with water, dried in vacuo and taken up in ethyl acetate ether. Dry hydrogen chloride gas is passed through the solution to separate crystals of lO-[3'-(N-w butyryloxybutylpiperazinyl) propyl] 2 trifluoromethylphenothiazine dihydrochloride.
10 EXAMPLE XVII A solution of 3.9 g. of 10-(3'-piperaziny1propyl)-2- trifluoromethylphenothiazine (made as in Example 111), in g. of benzene is swirled while 1.8 g. of phenylacetyl chloride is added dropwise. After standing overnight, the separated crystals of 10-[3-(N-phenylacetylpiperazinyl) propyl] -2-trifluoromethylphenothiazine hydrochloride are removed by filtration and washed with ether.
EXAMPLE XVIII A solution of 3.8 g. of 10-(2'-piperazinylethyl)-2-trifluoromethylphenothiazine (made as in Example V) in 150 g. of benzene with 4 ml. of pyridine is swirled while 3 ml. of acetic anhydride are added. The reaction mixture is allowed to stand overnight and evaporated to dryness. The residue after the usual acid extraction and neutralization is taken up in ethyl acetate and reacted with one equivalent of maleic acid to give 10-[2- (N acetylpiperazinyl) ethyl] 2 trifluoromethylphenothiazine maleate.
EXAMPLE )GX A solution of 8.6 g. of 10-[3'-(N-hydroxyethylpiperazinyl)-propyl]-2-trifluoromethylphenothiazine (made as in Example VII) in 50 g. of pyridine is swirled as 3.0 g. of benzoyl chloride is added. The reaction mixture, after standing for eight hours, is poured into a large volume of water. The material which separates is washed well with water, taken up in ether, and treated with ethereal hydrogen chloride to give crystals of 10-[3-(N- benzoyloxyethylpiperazinyl) propyl] 2 trifluoromethylphenothiazine dihydrochloride; melting point 226- 228" C.
EXAMPLE XX A suspension of 13.4 g. of 2-trifluoromethylphenothiazine, 2.3 g. of sodium amide and 13.7 g. of 3-chloro-1- (N methylpiperazinyl) 2 (a tetrahydropyranyloxy)-propane, prepared by reacting dihydropyrane with 3 chloro-2-hydroxy-1-(N-methylpiperazinyl)-propane in 450 ml. of toluene is heated at reflux with stirring for six hours. After working up, following the procedure of Example I, the residue is taken up and warmed on the steam bath with 10% hydrochloric acid for 15 minutes. Neutralization with sodium carbonate, extraction with benzene and evaporation of the solvent gives a viscous syrup. The base is taken up in ethyl acetate and reacted with an excess of maleic acid to give crystals of the dimaleate salt of 10-[2-hydroxy-3-(N-methylpiperazinyl)- propyl] -2-trifluoromethylphenothiazine.
EXAMPLE XXI A suspension of 26.7 g. of 2-trifluoromethylphenothiazine, 25.0 g. of N-carbethoxy-N-('y-chloro-fl-methylpropyl)-piperazine, prepared by condensing N-carbethoxypiperazine with 3-bromo-Z-methylpropylchloride, and 4.5 g. of sodium amide in 500 ml. of toluene is reacted and worked up-following the procedure of Example II to leave a dark oil, 10-[3'-(N-carbethoxypiperazinyl)-2'- methylpropyl] -2-trifluoromethylphenothiazine.
EXAMPLE XXII A portion of this base, 2.9 g., is dissolved in 75 ml. of
ethyl acetate and reacted with 3 g. of mandelic acid in 50 ml. of ethanol. The mixture is allowed to evaporate on the steam bath until the saltbegins to separate. Cooling yields 10-(2'-methyl-3'-piperazinylpropyl)-2-trifluoror methylphenothiazine dimandelate.
' A second portion of the base, 2.9 g., is dissolved in 75 ml. of ethyl acetate and mixed with ml. of alcoholic hydrogen bromide. Cooling gives the dihydrobromide salt of the base.
EXAMPLE XXIII A solution of 5.7 g. of -(2-methyl-3'-piperazinylpropyl)-2-trifluoromethylphenothiazine (made as in Example XXII), in 150 ml. of ethanol is warmed with 1.7 g. of ethylene oxide to 50 C. for one hour. The volatiles are removed in vacuo to leave 10-[3'-(N-hydroxyethylpiperazinyl) 2 methylpropyl] 2 trifluoromethylphenothiazine.
A solution of 1.6 g. of the base in 50 ml. of ether-benzene is heated at reflux with 1 ml. of acetyl chloride. The separated monohydrochloride of 10-[3'-(N-acetoxyethylpiperazinyl) 2' methylpropyl] 2 trifluoromethylphenothiazine is optionally isolated as such or shaken in an ethyl acetate-sodium carbonate solution mixture and converted to the dirnaleate salt with an excess of maleic acid.
A solution of 1.6 g. of the hydroxyethyl base in 50 ml. of ether-benzene is heated at reflux With 0.8 g. of benzoyl chloride. The hydrochloride of l0-[3'-(N- benzoyloxyethylpiperazinyl) 2' methylpropyl] 2 trifluoromethylphenothiazine is isolated as described above.
EXAMPLE XXIV A solution of 2.7 g. of 10-(3'-piperazinylpropyl)-2- trifluoromethylphenothiazine (made as in Example 111) and 1.5 g. of benzoyl chloride in 125 ml. of benzene is heated at reflux for several hours. Concentration and standing yields crystals of the hydrochloride of l0-[3'- (N benzoylpiperazinyl) propyl] 2 trifluoromethylphenothiazine.
Another aliquot containing 2.7 g. of the base and 1.2 g. of Z-furoyl chloride is reacted and Worked up as above to yield 10-[3'-(N-furoylpiperazinyl)-propyl]-2-t1ifluoromethylphenothiazine hydrochloride.
EXAMPE XXV A suspension of 36.7 g. of 2hepta-fluoropropylpheno thiazine (made as in Example XIV), 4.0 g. of sodium amide and 27.5 g. of N-diethylcarbamyl-N-('y-chloropropyl)-piperazine (prepared by reacting N-diethylcarbamylpiperazine with -chloropropyl bromide in xylene with sodium amide in 300 ml. of toluene is heated at reflux for six hours. The reaction mixture is Worked up following the procedure of Example I, but the hydrochloride salt is recovered and purified by crystallization to give 10 [3' N diethylcarbamylpiperazinyl) propyl] 2- heptafluoropropylphenothiazine hydrochloride. 7
EXAMPLE )QCV-I A solution of 53.0 g. of crude l0-[3-N-diethylcarbamylpiperazinyl) propyl] 2 heptafluoropropylphenothiazine hydrochloride (made as in Example XXV) in 200 ml. of concentrated hydrochloric acid is heated at reflux for 10 hours.. The solution is diluted with Water and filtered. The filtrate is neutralized With 40% sodium hydroxide'solution. The separated product is taken up in chloroform, dried and treated with hydrogen chloride gas. to separate ,Z-heptafluoropropyl-l0-(3'-piperazinylpropyl)-phenothiazine dihydrochloride.
. A suspension of 5.8 g. of this salt in 50 ml. of toluene with 1.8 g. of fi-bromoethyl acetate and 2.0 g. of potassium carbonate is heated at reflux,'with stirring, for 12 hours. After Working up as in Example IV, crystals of 10 [3 (N acetoxyethylpiperazinyl) propyl] 2- heptafluoropropylphenothiazine dihydrochloride are recovered.
12 EXAMPLE XXVI I A solution of 2.7 g. of 2-trifluoromethylphenothiazine, 2.2 g. of 2-ch1oro-1(1',2,3',5 ',6'-pentamethylpiperazinyl) ethane and 0.75 g. of sodium amide in 50 ml. of henzene is stirred and heated at reflux for eight hours. After Working up as in Example I, micromolecular distillation at 190 C. and 5 microns gives 10-[2-(l,2, 3,5",6" pentamethylpiperazinyl) ethyl] 2 trifluoromethylphenothiazine as a viscous tar.
EXAMPLE XXVIII A suspension of 8.0 g. of l0-(2'-piperazinylethyl)-2- trtifluoromethylphenothiazine, 1.8 g. of potassium carbonate and 1.6 g. of allyl chloride in ml. of aqueous ethanol is stirred at reflux for three hours. After Working up as described in Example XV, crystals of l0-[2- (N allylpiperazinyl) ethyl] 2 trifluoromethylpheno: thiazine dihydrochloride are obtained.
1 EXAMPLE XXX EXAMPLE XXXl A suspension of 26.7 g. of Z-trifluoromethylphenothiazine in 600 ml. of. toluene With 4.5 g. of sodium amide is heated at reflux and then reacted for six hours With 35.2 g. of 4-carbobenzoxy-l-w-chloropropyl)-2,5-diethylpiperazine, prepared by reacting N-carbobenzoxy-2,5-diethylpiperazine with y-chloropropyl bromide in benzene with sodium amide. The reaction mixture containing 10 [3' (N-carbobenzoxy 2",5 diethylpiperazinyD- propyl]-2-trifluoromethylphenothiazine is 'Washed With Water and treated with dilute hydrochloric acid. The acid extracts are warmed briefly, cooled and treated With sodium hydroxide solution. The separated base is taken up in ethyl acetate, dried and micromolecularly distilled to give the thick base 10-[3'-(27,5":diethylpiperazinyl)- propyl]-2-trifluoromethylphenothiazine. V A solution of 3.2 g. of the base in 75 ml. of benzene is heated at reflux with 1.2 g. of isocrotonyl chloride with sodium carbonate for several hours. The reaction mixture is treated with dilute hydrochloric acid after neutralization. The product is taken up in ethyl acetate, dried and reacted With maleic acid to give 10-'[3'(N- isocrotonyl 2",5" diethylpiperazinyl) propyl] 2- trifluoromethylphenothiazine .dimaleate.
Another solution of 3.2 g. of the base in 75 ml. of benzene is reacted With 1.5 g. of dichloroacetyl chloride as above to give the monohydrochloride salt of 10'-[3'- (N-dichloroacetyl 2,5' diethylpiperazinyl) propyl]- Z-trifluoromethylphenothiazine.
A solution of 5.0 g. of the base in 50 ml. of formalinformic acid mixture is warmed on the steam bath until the evolution of gas ceases; The mixture is neutralized and extracted with dilute hydrochloric acid. The acid extracts g. of Z-trifluoromethylpheno 1 fluoromethylphenothiazine dihydrobromide.
EXAMPLE XXXH A solution of 31.1 g. of 10-[3-(N-hydroxyethylpiperazinyl)propyl]-2atrifluoromethylphenothiazine in 500 ml. of benzene is prepared as in Example VII. From the stock solution, an aliquot solution containing 3.2 g. of the hydroxyethyl compound is heated briefly at reflux with 1.0 g. of propionyl chloride. A small excess of ethanolic hydrogen chloride is added. The precipitated product is 10-[3'-(N-propionyloxyethylpiperazinyl)-propyl] 2 trifluoromethylphenothiazine dihydrochloride, M.P. 2l2-214 C.
A second aliquot solution containing 3.2 g. of the hydroxyethyl base is reacted with 1.5 g. of dichloroacetyl chloride as above. The product is 10-[3-(N-dichloroacetoxyethylpip er azinyl) -propy-l] -2-trifluoromethylphenothiazine dihydrochloride.
Another aliquot solution containing 3.2 g. of the hydroxyethyl base is reacted with 1.2 g. of chloroacetyl chloride. The product is 10-[3-(N-chloroacetoxyethyl- 'piperazinyl) -propyl] -2 trifluoromethylphenothiazine dihydrochloride, M.P. 191-192 C.
Another aliquot solution containing 3.2 g. of the hydroxyethyl base is reacted with 1.5 g. of chloroethyl chloroformate. The product is l-[3-(N-chloroethylcarbonyldioxyethylpiperazinyl) -propyl] -2 trifluoromethylphenothiazine dihydrochloride.
Crotonic chloride, 1.0 g., is reacted with an aliquot of the hydroxyethyl base as above. The separated monohydrochloride of [3'-(N-crotonyloxyethylpiperazinyl)- propyl]-2 trifluoromethylphenothiazine is separated by filtration and washed with ether.
EXAMPLE XXXIII A suspension of 2.7 g. of 10-(3'-piperazinylpropyl) -2- trifluoromethylphenothiazine (Example III) in 50 ml. of dimethyl formarnide with 1.0 g. of potassium carbonate is stirred while 1.3 g. of benzyl chloride is added. The solution is heated at 80 C. for four hours and poured into an excess of water. The resulting precipitate is washed and extracted into benzene. An excess of hydrogen chloride in ethyl acetate gives 10-[3'-(Nbenzylpiperazinyl) -propyl] -2 trifluoromethylphenothiazine dihydrochloride.
Another portion of 2.7 g. of the base is reacted with 1.9 g. of phenethyl bromide, as above, to give 10-[3'-(N phenethylpiperazinyl)propyl] 2 trifluoromethylphenothiazine dihydrochloride.
Another portion (2.7 g.) is talkylated with 2.2 g. of w-phenylbutyl bromide to give the N-w-phenylbutyl analogue.
The base (5.4 g.) is alkylated with 2.6 g. of thenyl chloride as above. The dim-aleate salt of 10-[3'-(N- thenyl-piperazinyl)-propyl] 2 trifluoromethylphenothiazine is obtained by reacting the crude base with an excess of maleic acid in ethyl acetate solution.
EXAMPLE XXXIV A solution of 2.8 g. of 1'0-(2-methyl-3piperazinylpropyl)-2-trifluoromethylphenothiazine (Example XXII) and 1.6 g. of cyclopentyl-propionyl chloride in 50 ml. of benzene is heated at reflux for three hours. The solid separates to give crystals of 10-[3'-(N-cyclopenty1propionylpiperazinyl)-2-methylpropyl] 2 trifluoromethylphenothiazine hydrochloride.
Another solution of 2.8 g. of the base is reacted with 1.5 g. of hexahydrobenzoyl chloride, as above, to give the hydrochloride of l0-[3'-(N-hexahydrobenzoylpiperazinyl)-2-methyl -propyl] 2 trifluoromethylphenothiazine.
The base (-2.8 g.) is reacted with 2.0 g. of B-cyclohexylethyl bromide in dimethylformamide and =l.0 g. of potassium carbonate is reacted and the product isolated as described in Example XV to give the dimaleate salt of 10-[3-(N-cyclohexylethylpiperazinyl) 2' methylpropyl]-2-trilluoromethylphenothiazine.
EXAMPLE XXXV A solution of 3.4 g. of 10-[3-(N-hydroxybutylpiperazinyl)-propyl] -2 trifluoromethylphenothiazine (Example XVI) in 25 ml. of benzene is reacted with 2.3 g. of furoyl chloride in 25 m1. of benzene at reflux for two hours. The hydrochloride of 10-[3'-(N-furoy1oxybutylpiperazinyl) propyl] -2-trifluoromethylphenothiazine separates as a crystalline solid.
EXAMPLE XXXVI A solution of 3.4 g. of the hydroxyethyl base of Example VII is reacted with 1.2 g. of isocaproyl chloride tollowing the procedure above to give the hydrochloride salt of 10-[3-(N-isocaproyloxyethylpiperazinyl) -propyl]- 2-trifluoromethylphenothiazine as a crystalline solid.
EXAMPLE XXXVII A suspension of 15.4 g. of 10-(3-piperazinylpropyl) -2- trifluoromethylphenothiazine in 7.5 ml. of concentrated hydrochloric acid and 100 ml. of Water is heated to C. The volume of the reaction mixture is brought to 500 ml. with water. Ethanol ml.) is added along with 3.6 g. of potassium cyanate in 25 ml. of water. After refluxing for one hour, the solvent is removed. The cooled reaction mixture is neutralized with ammonium hydroxide. The suspension is extracted with chloroform. The dried chloroform extract is evaporated to leave crystals of 10-[3-(N-carbamylpiperazinyl)-propyl] -2-triflu oromethylphenothiazine.
This application is a continuation-in-part of application Serial No. 576,792, filed April 9, 1956, now US. Patent No. 2,921,069.
What is claimed is:
1. 10[3'-(4-B-hydroxyethyl piperazinyl) propyl]-2-trifluoromethyl phenothiazine.
2. Chemical compounds of the class consisting of a free base and its nontoxic acid addition salts, the free base having the formula:
in which Y is perfluoroalkyl of 1 to 3 carbon atoms; A is an alkylene chain of from 2 to 6 carbon atoms separating the nitrogen atoms linked thereto by at least two carbon atoms; and R is a member selected from the group consisting of cycloalkyl-lower-alkyl, the cycloalkyl portion having 5 to 6 carbon atoms and the lower-alkyl portion having 1 to 4 carbon atoms, lower alkenyl having 3 to 6 carbon atoms, hydroxy-lower-allcyl having 2 to 6 carbon atoms in the alkyl portion, hydroxy-lower-alkyloxy-lower-alkyl, the lower alkyl portions having 2 to 6 carbon atoms, phenyl, phenyl-lower-alkyl having 1 to 6 carbon atoms in the alkyl portion, lower-alkanoyl having 1 to 6 carbon atoms, cycloalkyl-lower-alkanoyl, the cycloalkyl portion having 5 to 6 carbon atoms and the loweralkanoyl portion having 2 to 4 carbon atoms, phenyllower-alkanoyl, the lower alkanoyl portion having 2 to 4 carbon atoms, benzoyl, carbomethoxy, carbethoxy, carbobenzoxy, carbamyl, dialkyl-carbamyl having 1 to '6 carbon atoms in the alkyl portions, N-phenyl-carbamyl, loweralkanoyloxy-lower-alkyl, the lower-alkanoyloxy portion having 2 to 6 carbon atoms and the lower-alkyl portion having 2 to 6 carbon atoms and benzoyloxy-lower-alkyl l 16 having 2 to 6 carbon atoms inthe-lower alkyl portion. -8,.A chemical compound of the formula: V
3. A chemical compound of the formula: /S v a 5 I on a m 7 OHzOHzOHa-N N-0HO- I m a *lower'alkYl'h-Ydmxy 9 A chemical com ound f the formula" V p o in which A is an alkylene chain of from 2 to 6 carbon 10 atoms separating the nitrogen atoms linked thereto by at least two carbon atoms and the lower-alkyl portion 7 on has 2 to 6 carbon atoms. N
4. A chemical compound of the formula: (IJHZOHQHPN 0235 10. A chemical compound of the formula: a gom r I v s p A-N N lower-a1k3ilcry-lower-alkyl-hydroxy O @C F Y W p N a in which A is an alkylene chain of from 2 to 6 carbon 1 (BHZOHZOHPN 4105132 atoms separating the nitrogen atoms linked thereto by a at least two carbon atoms and each of the lower-alkyl 11, A hemical'compound of the formula: portions have 2 to 6 carbon .atoms. S 1 5. A chemical compound of the formula: I 7 l I v fi "orr- I p N/ OF3 OHrOHzGHz N 'N( lH zclH-zo CzH l \N 1OWelmalkyl'dowepalkanoyloxy 12. Achemical compound of the formula: 1 s V in which A is an alkylene chain of from 2 to 6 carbon v atoms separating the nitrogen atoms linked thereto by f v at least two carbon atoms; the lower-alkyl portion having N a a o 2 to 6 carbon atoms and the lower-alkanoyloxy portion 7 'fi (15011201 having 2 to 6 carbon atoms. 40 V v, 6. A chemical compound of the formula: H v S I V V References Cited 1n the file of this patent I v UNITED STATES PATENTS OF 2,766,235 Cusic Oct. 9, 1956 a 0 7 2,902,485 Horclois Sept. 1, 1959 (gHflcHzoHrN/ \Nwmomogom 2. 2 uy t an.12,196o
LJ v FOREIGN PATENTS 7. A chemical compound of the formula: 293/55 South Africa Au0 22 1955 v V V a- I /S CF11 i N j p I

Claims (1)

  1. 2. CHEMICAL COMPOUNDS OF THE CLASS CONSISTING OF A IN WHICH Y IS PERFLUOROALKYL OF 1 TO 3 CARBON ATOMS; A FREE BASE AND ITS NONTOXIC ACID ADDITION SALTS, THE FREE BASE HAVING THE FORMULA: IN WHICH Y IS PERFLUOROALKYL OF 1 TO 3 CARBON ATOMS; A IS AN ALKYLENE CHAIN OF FROM 2 TO 6 CARBON ATOMS SEPARATING THE NITROGEN ATOMS LINKED THERETO BY AT LEAST TWO CARBON ATOMS; AND R6 IS A MEMBER SELECTED FROM THEHAVGROUP CONSISTING OF CYCLOALKYL-LOWER-ALKYL, THE CYCLOALKYL PORTION HAVING 5 TO 6 CARBON ATOMS AND THE LOWER-ALKYL PORTION HAVING 1 TO 4 CARBON ATOMS, LOWER ALKENYL HAVING 3 TO 6 CARBON ATOMS, HYDROXY-LOWER-ALKYL HAVING 2 TO 6 CARBON ATOMS IN THE ALKYL PORTION, HYDROXY-LOWER-ALKYLOXY-LOWER-ALKYL, THE LOWER ALKYL PORTIONS HAVING 2 TO 6 CARBON ATOMS, PHENYL, PHENYL-LOWER-ALKYL HAVING 1 TO 6 CARBON ATOMS, IN THE ALKYL PORTION, LOWER-ALKANOYL HAVING 1 TO 6 CARBON ATOMS, CYCLOALKYL-LOWER-ALKANOYL, THE CYCLOALKYL PORTION HAVING 5 TO 6 CARBON ATOMS AND THE LOWER ALKANOYL PORTION HAVING 2 TO 4 CARBON ATOMS, PHENYLLOWER-ALKANOYL, THE LOWER ALKANOYL PORTION HAVING 2 TO 4 CARBON ATOMS, BENZOYL, CARBOMETHOXY, CARBETHOXY, CARBOBENZOXY, CARBAMYL, DIALKYL-CARBAMYL HAVING 1 TO 6 CARBON ATOMS IN THE ALKYL PORTIONS, N-PHENYL-CARBAMYL, LOWERALKANOYLOXY-LOWER-ALKYL, THE LOWER-ALKANOYLOXY PORTION HAVING 2 TO 6 CARBON ATOMS AND THE LOWER-ALKYL PORTION HAVING 2 TO 6 CARBON ATOMS AND BENZOYLOXY-LOWER-ALKYL HAVING 2 TO 6 CARBON ATOMS IN THE LOWER ALKYL PORTION.
US658526A 1957-05-13 1957-05-13 New perfluoroalkylphenothiazine derivatives Expired - Lifetime US3058979A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US658526A US3058979A (en) 1957-05-13 1957-05-13 New perfluoroalkylphenothiazine derivatives
GB32856/57A GB829246A (en) 1957-05-13 1957-10-21 Improvements in or relating to new perfluoroalkyl-phenothiazine derivatives
FR765378A FR1293508A (en) 1957-05-13 1958-05-12 Process for the manufacture of 10- [3 '- (n-hydroxyethylpiperazinyl) -propyl] -2-trifluoromethylphenothiazine derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US658526A US3058979A (en) 1957-05-13 1957-05-13 New perfluoroalkylphenothiazine derivatives

Publications (1)

Publication Number Publication Date
US3058979A true US3058979A (en) 1962-10-16

Family

ID=24641614

Family Applications (1)

Application Number Title Priority Date Filing Date
US658526A Expired - Lifetime US3058979A (en) 1957-05-13 1957-05-13 New perfluoroalkylphenothiazine derivatives

Country Status (2)

Country Link
US (1) US3058979A (en)
GB (1) GB829246A (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152126A (en) * 1963-01-14 1964-10-06 Olin Mathieson New diesters of phenothiazines
US3194733A (en) * 1961-04-26 1965-07-13 Olin Mathicson Chemical Corp Phenothiazine compositions and method of treating mental disorders
US3282934A (en) * 1964-05-15 1966-11-01 Schering Corp Nitrogenous esters of hydroxylalkylamino phenothiazines
US3317537A (en) * 1965-06-25 1967-05-02 Colgate Palmolive Co Piperazinoalkyl-morphanthridines
US3394131A (en) * 1961-04-26 1968-07-23 Squibb & Sons Inc Acid esters of phenothiazine
US5059600A (en) * 1989-03-31 1991-10-22 Yale University Treating habit disorders
US5114942A (en) * 1989-03-31 1992-05-19 Yale University Treating habit disorders
US5223497A (en) * 1989-03-31 1993-06-29 Yale University Treating habit disorders
WO1998015546A1 (en) * 1996-10-04 1998-04-16 Novo Nordisk A/S N-substituted azaheterocyclic compounds
US5874445A (en) * 1990-06-01 1999-02-23 Merrell Pharmaceutical, Inc. (+) -α- (2,3-dimethoxyphenyl)-1-(2-(4-fluorephenyl) ethyl)-4-piepridinemethanol
US6004980A (en) * 1990-06-01 1999-12-21 Merrell Pharmaceuticals, Inc. (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
EP1534256A2 (en) * 2002-06-17 2005-06-01 Philadelphia Health and Education Corporation Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier
US20060258639A1 (en) * 2005-04-22 2006-11-16 Wyeth Therapeutic combinations for the treatment or prevention of psychotic disorders
US20060276460A1 (en) * 2003-04-25 2006-12-07 Noelle Callizot Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on cns and/or pns
US20080125415A1 (en) * 2006-09-01 2008-05-29 Immune Control, Inc. Novel methods for treatment of diseases related to activated lymphocytes
US20100035859A1 (en) * 2007-02-01 2010-02-11 Pad Pharma Limited Treatment of protein aggregation diseases
WO2013138101A2 (en) 2012-03-16 2013-09-19 Children's Medical Center Corporation Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
EP3574920A1 (en) * 2018-05-31 2019-12-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nupr1 inhibition for treating cancer

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
WO2008010223A2 (en) 2006-07-17 2008-01-24 Ramot At Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders
US8207369B2 (en) 2008-02-11 2012-06-26 Ramot At Tel-Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
US8975251B2 (en) 2009-12-09 2015-03-10 Bar-Ilan University Methods of improving cognitive functions
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
CN105153062A (en) * 2015-10-10 2015-12-16 江苏宝众宝达药业有限公司 Preparation method of permitil

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2766235A (en) * 1956-06-21 1956-10-09 John W Cusic N-(beta-acetoxyethyl)-n'-(chlorophenothiazinepropyl) piperazine
US2902485A (en) * 1954-04-27 1959-09-01 Rhone Poulenc Sa Phenthiazine derivatives
US2921069A (en) * 1956-04-09 1960-01-12 Smith Kline French Lab Substituted trifluroromethylpheno-thiazine derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2902485A (en) * 1954-04-27 1959-09-01 Rhone Poulenc Sa Phenthiazine derivatives
US2921069A (en) * 1956-04-09 1960-01-12 Smith Kline French Lab Substituted trifluroromethylpheno-thiazine derivatives
US2766235A (en) * 1956-06-21 1956-10-09 John W Cusic N-(beta-acetoxyethyl)-n'-(chlorophenothiazinepropyl) piperazine

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3194733A (en) * 1961-04-26 1965-07-13 Olin Mathicson Chemical Corp Phenothiazine compositions and method of treating mental disorders
US3394131A (en) * 1961-04-26 1968-07-23 Squibb & Sons Inc Acid esters of phenothiazine
US3152126A (en) * 1963-01-14 1964-10-06 Olin Mathieson New diesters of phenothiazines
US3282934A (en) * 1964-05-15 1966-11-01 Schering Corp Nitrogenous esters of hydroxylalkylamino phenothiazines
US3317537A (en) * 1965-06-25 1967-05-02 Colgate Palmolive Co Piperazinoalkyl-morphanthridines
US5059600A (en) * 1989-03-31 1991-10-22 Yale University Treating habit disorders
US5114942A (en) * 1989-03-31 1992-05-19 Yale University Treating habit disorders
US5223497A (en) * 1989-03-31 1993-06-29 Yale University Treating habit disorders
US6004980A (en) * 1990-06-01 1999-12-21 Merrell Pharmaceuticals, Inc. (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US5874445A (en) * 1990-06-01 1999-02-23 Merrell Pharmaceutical, Inc. (+) -α- (2,3-dimethoxyphenyl)-1-(2-(4-fluorephenyl) ethyl)-4-piepridinemethanol
WO1998015546A1 (en) * 1996-10-04 1998-04-16 Novo Nordisk A/S N-substituted azaheterocyclic compounds
US6569849B1 (en) 1996-10-04 2003-05-27 Novo Nordisk A/S N-Substituted azaheterocyclic compounds
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
US6063793A (en) * 1997-07-25 2000-05-16 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidi nemethanol
EP1534256A2 (en) * 2002-06-17 2005-06-01 Philadelphia Health and Education Corporation Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier
JP2005538065A (en) * 2002-06-17 2005-12-15 フイラデルフイア・ヘルス・アンド・エデユケーシヨン・コーポレーシヨン Immunoregulation of serotonin family receptors and blood-brain barrier and effects on cellular processes
EP1534256A4 (en) * 2002-06-17 2007-06-20 Philadelphia Health & Educatio Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier
US20060276460A1 (en) * 2003-04-25 2006-12-07 Noelle Callizot Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on cns and/or pns
US20060258639A1 (en) * 2005-04-22 2006-11-16 Wyeth Therapeutic combinations for the treatment or prevention of psychotic disorders
US7981885B2 (en) 2006-09-01 2011-07-19 Immune Control Inc. Compositions for treatment of diseases related to activated lymphocytes
US20080132697A1 (en) * 2006-09-01 2008-06-05 Immune Control, Inc. Novel compositions for treatment of diseases related to activated lymphocytes
EP2061788A1 (en) * 2006-09-01 2009-05-27 Immune Control, Inc. Novel compositions and methods for treatment of diseases related to activated lymphocytes
US20080125415A1 (en) * 2006-09-01 2008-05-29 Immune Control, Inc. Novel methods for treatment of diseases related to activated lymphocytes
EP2061788A4 (en) * 2006-09-01 2010-10-06 Immune Control Inc Novel compositions and methods for treatment of diseases related to activated lymphocytes
US7923445B2 (en) 2006-09-01 2011-04-12 Immune Control, Inc. Methods for treatment of diseases related to activated lymphocytes
US20100035859A1 (en) * 2007-02-01 2010-02-11 Pad Pharma Limited Treatment of protein aggregation diseases
US8383617B2 (en) 2007-02-01 2013-02-26 Pad Pharma Limited Treatment of protein aggregation diseases
WO2013138101A2 (en) 2012-03-16 2013-09-19 Children's Medical Center Corporation Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
EP3461482A1 (en) 2012-03-16 2019-04-03 Children's Medical Center Corporation Calcium channel blockers for the treatment of ribosomal disorders and ribosomapathies
EP3574920A1 (en) * 2018-05-31 2019-12-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nupr1 inhibition for treating cancer
WO2019229236A1 (en) * 2018-05-31 2019-12-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nupr1 inhibition for treating cancer
CN113164492A (en) * 2018-05-31 2021-07-23 国家医疗保健研究所 NUPR1 inhibition for the treatment of cancer

Also Published As

Publication number Publication date
GB829246A (en) 1960-03-02

Similar Documents

Publication Publication Date Title
US3058979A (en) New perfluoroalkylphenothiazine derivatives
US2921069A (en) Substituted trifluroromethylpheno-thiazine derivatives
NO155805B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVITY 2- (4- (DIPHENYLMETHYL) -1-PIPERAZINYL) -ACDIC ACIDS AND THEIR AMIDS AND NON-TOXIC SALTS.
US3347849A (en) 5-(basic substituted)-dibenzodiazepines
US3192204A (en) Trifluoromethylthiaxanthene and -xanthene derivatives
US3074931A (en) Dibenzazepines
US2877224A (en) 3-cyano substituted phenothiazines
US3120540A (en) Bis (polymethyl)-4-piperidinol alkanoates
US3923813A (en) Derivatives of 2-aminoindanes
US2889322A (en) 3-methanesulphonyl phenthiazine derivatives
US3063996A (en) Substituted piperidinylalkyl phenothiazines
CA2141210A1 (en) Novel piperazine carboxamides
US2956996A (en) Alkylated phenotfflazenecarboxamede
US2694705A (en) Nx c c ox a a
US3068222A (en) Trifluoromethyl substituted dibenzxze-
US2914528A (en) Substituted phenothiazinyl trifluoro-methyl sulfones
US2898336A (en) Phenthiazine derivatives
US2979502A (en) Phenthiazine derivatives
US3043842A (en) Substituted acridans
US2894947A (en) Phenthiazine derivatives
US2919272A (en) Substituted phenothiazinyl trifluoromethyl sulfones
US2926164A (en) N-(chlorophenothiazinealkyl)-3 and 4-(hydroxy alkyl)piperidines
FR2522000A1 (en) NOVEL THIOPYRANNOPYRIMIDINES, PARTICULARLY USEFUL AS HYPOGLYCEMIC AGENTS, AND THEIR MANUFACTURE
US3320247A (en) Phenthiazine compounds
US2787617A (en) Derivatives of oxopiperazinoalkylhalophenothiazines